Lorazepam
| Drug Category | Drug | IHD Dosing | Administration Timing Around HD Session |
|---|---|---|---|
| Sedatives | Lorazepam | 0.5-1mg PO Q8H PRN | Administer Anytime During HD |
Molecular Weight (Da) | Excreted Unchanged (%) | Normal Half-Life (Hours) | ESRD Half-Life (Hours) | Plasma Protein Binding (%) | Volume of Distribution (L/kg) | Dialytic Plasma Clearance (ml/min) | % Dialyzed |
|---|---|---|---|---|---|---|---|
| 321 | <1 | 5-10 | 32-70 | 87 | 0.9-1.3 | 82 | 8 (low flux) |
References:
- Aronoff GR, Bennett WM, Berns JS, Brier ME, Kasbekar N, Mueller BA, et al. Drug Prescribing in Renal Failure. Philadelphia: American College of Physicians;2007.
- DrugBank [Online]. 2012 Apr 12 [cited 2012 May 6]; Available from: URL: http://www.drugbank.ca/drugs/DB00186
- Morrison G, Chiang S, Koepke H, Walker B. Effect of renal impairment and hemodialysis on lorazepam kinetics. Clinical Pharmacology and Therapeutics. 1984;35(5):646-652.